| Today’s Big NewsJul 12, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Grab your pass today!
|
|
| By Annalee Armstrong Pfizer gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release formulation of oral med danuglipron will be advanced into dose optimization studies. |
|
|
|
By Nick Paul Taylor Immutep has spotted a potential niche for its LAG3 drug candidate, reporting phase 2b data in a subset of head and neck cancer patients to partly wipe away the stain left by an earlier readout. |
By Annalee Armstrong,Darren Incorvaia After leading Pfizer’s R&D unit through the pandemic, Chief Scientific Officer Mikael Dolsten, M.D., Ph.D., is heading out. |
By Helen Floersh The Biomedical Advanced Research and Development Authority has awarded a $749,999 contract to Cambridge-based Tiba Biotech to develop new a RNAi-based therapeutic against bird flu. |
By Ayla Ellison,Eric Sagonowsky,Fraiser Kansteiner In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.” |
By Zoey Becker The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition. |
By Noah Tong Industry leaders and legal observers are still coming to terms with the Supreme Court's landmark decision to overturn the Chevron doctrine. |
By Conor Hale Looking to be more upstart than startup, Element Biosciences aims to take on the DNA sequencing giant located right down the road in San Diego. |
By Angus Liu In the past two weeks, Bristol Myers Squibb has returned Eisai's FRα-targeted antibody-drug conjugate. In addition, Takeda telegraphed plans to lay off 220 employees in Massachusetts, while U.S. House Speaker Mike Johnson pledged a full floor vote on the BIOSECURE Act this year. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.” |
|
|---|
|
|
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
